Press release
United States Bacterial Infectious Diseases Therapeutics Market with CAGR of 8.2% during 2024-2031 - Exclusive Report by DatamIntelligence
Bacterial Infectious Diseases Therapeutics Market
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/bacterial-infectious-diseases-therapeutics-market?sp
United States: Recent Industry Developments
✅ In October 2025, Pfizer announced the launch of a next-generation antibiotic, Zobaxin, targeting multidrug-resistant bacterial infections in hospitals. The launch is part of a major push to combat escalating resistance and improve patient outcomes for critical care settings.
✅ In September 2025, Johnson & Johnson invested $150 million in a startup developing CRISPR-based therapeutics for drug-resistant tuberculosis. The investment aims to accelerate novel pipeline therapies and strengthen the company's leadership in infectious disease innovation.
✅ In August 2025, Merck introduced a partnership with the CDC to advance vaccine technologies against emerging bacterial pathogens, with a focus on rapid-response vaccine platforms. The partnership enhances U.S. readiness to address future infectious disease threats.
✅ In July 2025, GSK completed the acquisition of a Boston-based biotech firm specializing in antibiotics for superbug infections, boosting its infectious disease portfolio. The acquisition expands GSK's commercial reach and pipeline capacity for hospital-acquired infections.
Japan: Recent Industry Developments
✅ In October 2025, Shionogi & Co. launched Cefiderocol+, a new antibiotic designed for carbapenem-resistant bacteria, receiving fast-track approval for hospital use. The launch supports Japan's initiatives against healthcare-associated infections and antibiotic resistance.
✅ In September 2025, Daiichi Sankyo invested in developing antibody-based therapeutics for invasive bacterial diseases, focusing on pediatric and immunocompromised patients. The program advances Japan's strategy for targeted infectious disease treatment.
✅ In August 2025, Takeda Pharmaceuticals unveiled a joint research venture with Tokyo University to develop oral antivirulence therapies intended to prevent bacterial colonization and infection. The initiative aims to diversify Japan's infectious disease therapeutic options.
✅ In July 2025, Astellas Pharma completed acquisition of a domestic biotech startup working on diagnostic and therapeutic solutions for multi-drug resistant bacteria, strengthening Japan's innovation ecosystem in bacterial infection management.
Bacterial Infectious Diseases Therapeutics Market: Drivers
The bacterial infectious diseases therapeutics market is witnessing significant growth as the prevalence of bacterial infections, antibiotic resistance, and hospital-acquired infections continues to rise globally. Therapeutics in this segment include antibiotics, novel antibacterial agents, and adjunctive therapies designed to treat infections caused by resistant and multidrug-resistant bacterial strains. Increasing awareness about infectious disease management, rising healthcare expenditure, and demand for effective treatment options are driving market adoption. Technological advancements in drug discovery, targeted therapies, and formulation development are enhancing efficacy, safety, and patient compliance. Additionally, government initiatives, regulatory support, and global health programs aimed at combating bacterial infections are further supporting market expansion.
Integration of bacterial therapeutics with rapid diagnostic tools, personalized treatment approaches, and antimicrobial stewardship programs is improving patient outcomes and reducing resistance development. Pharmaceutical companies are investing heavily in research and development of next-generation antibiotics, combination therapies, and biologics to address emerging resistant pathogens. Growing prevalence of chronic conditions, immunocompromised populations, and hospital-acquired infections is fueling demand for innovative therapeutics. Collaborations between biotech firms, healthcare institutions, and research organizations are accelerating the development and commercialization of effective treatments. With rising bacterial infection rates, antibiotic resistance challenges, and continuous innovation, the bacterial infectious diseases therapeutics market is poised for strong and sustained growth in the coming years.
Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/bacterial-infectious-diseases-therapeutics-market?sp
Bacterial Infectious Diseases Therapeutics Market: Major Players
Novartis AG, GlaxoSmithkline Plc, Pfizer Inc, Merck & Co., Inc., Sanofi, Allergan, Bayer AG, AstraZeneca Plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Johnson and Johnson, and Teva Pharmaceuticals Indust
Segment Covered in the Bacterial Infectious Diseases Therapeutics Market:
➥ By Disease Type: Bacterial Skin Infections, Foodborne Bacterial Infections, Sexually Transmitted Bacterial Infections, Others
➥ By Therapeutics: Beta-Lactam, Quinolones, Macrolides, Tetracyclines, Sulfonamide, Others
➥ By Route of Administration: Oral, Topical, Parenteral, Others
➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others
Research Process:
Both primary and secondary data sources have been used in the Bacterial Infectious Diseases Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Most Frequently Asked Questions in the Bacterial Infectious Diseases Therapeutics Market Research Industry:
➠ Who leads the Bacterial Infectious Diseases Therapeutics industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Bacterial Infectious Diseases Therapeutics market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Bacterial Infectious Diseases Therapeutics market growth?
➠ What are the dominant sales and distribution strategies in the Bacterial Infectious Diseases Therapeutics industry?
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=bacterial-infectious-diseases-therapeutics-market
Regional Analysis:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Bacterial Infectious Diseases Therapeutics Market with CAGR of 8.2% during 2024-2031 - Exclusive Report by DatamIntelligence here
News-ID: 4236211 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
United States Silk Market to Grow at 3.2% CAGR Through 2031 | Asia-Pacific Leads …
Market Overview
The Global Silk Market is projected to grow at a CAGR of 3.2% during the forecast period 2024-2031. Mulberry silk dominates global production, accounting for the majority of commercially produced silk, with governments promoting its cultivation to meet rising demand. While China remains the largest silk producer, India's climatic conditions are particularly favorable for mulberry silk cultivation, offering significant growth potential.
Get a Free Sample PDF Of This Report (Get…
Sericulture Market to Reach USD 468.4 Billion by 2031 | CAGR 8.1% | Asia-Pacific …
Sericulture Market Overview
The Global Sericulture Market reached US$ 251.2 billion in 2022 and is projected to reach US$ 468.4 billion by 2031, growing at a CAGR of 8.1% during the forecast period 2024-2031. Traditionally focused on textiles, the sericulture market is witnessing significant product diversification, with silk being used in cosmetics, medical devices, and industrial applications. This expansion beyond conventional fabrics is a key trend supporting market growth, as it…
Advanced Carbon Materials Market to Reach USD 26.8 Billion by 2031 | CAGR 8.8% | …
Advanced Carbon Materials Market Overview
The Global Advanced Carbon Materials Market reached US$ 15.9 billion in 2023 and is projected to reach US$ 26.8 billion by 2031, growing at a CAGR of 8.8% during the forecast period 2024-2031. Advanced carbon materials such as graphite, carbon fiber, carbon nanotubes, graphene, and diamond are widely used across multiple industries due to their exceptional mechanical strength, stiffness, thermal stability, and low density. Their superior…
High Early Strength Cement (HE) Market to Reach USD 2.3 Billion by 2031 | CAGR 4 …
Market Size & Overview
The Global High Early Strength Cement (HE) Market reached US$ 1.5 billion in 2022 and is projected to reach US$ 2.3 billion by 2031, growing at a CAGR of 4.7% during the forecast period 2024-2031. High early strength cement is a specialized cement variant designed to achieve faster setting and early strength development, making it ideal for projects requiring quick construction or maintenance. It is extensively used…
More Releases for Bacterial
Prominent Bacterial Conjunctivitis Market Trend for 2025: Innovative Eye Drops T …
What Are the Projected Growth and Market Size Trends for the Bacterial Conjunctivitis Market?
The bacterial conjunctivitis market has grown steadily, projected to expand from $4.52 billion in 2024 to $4.76 billion in 2025, at a CAGR of 5.3%. Growth factors include rising bacterial infection cases, improved diagnostics, patient education programs, stringent regulatory frameworks, and physician training.
The bacterial conjunctivitis market is projected to grow steadily, reaching $5.54 billion by 2029 at…
Community-Acquired Bacterial Pneumonia Market
DelveInsight's "Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Community-Acquired Bacterial Pneumonia market report provides current treatment practices, emerging drugs, Community-Acquired Bacterial Pneumonia market share of the individual therapies, and current…
Bacterial Conjunctivitis Drugs Market Report 2018: Segmentation by Disease Type …
Global Bacterial Conjunctivitis Drugs market research report provides company profile for Pfizer Inc., Novartis AG, F. Hoffmann-La Roche, Bayer Healthcare, Valeant Pharmaceutical International Inc., Perrigo Company Plc, Akorn Inc., Santen Pharmaceutical Co. Ltd., Allergan Plc. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth…
Bacterial Conjunctivitis Drugs Market: Rising Incidence of Ophthalmic Bacterial …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as…
Bacterial Conjunctivitis Drugs Market Driven by Rising Incidence of Ophthalmic B …
The U.S. market for bacterial conjunctivitis drugs is extremely fragmented, leading to commensurate competition among players. The entry barriers faced by new players despite having good research and development capabilities, is lack of capital, Transparency Market Research (TMR) states in its new report on the U.S. market for bacterial conjunctivitis drugs. R&D involves huge costs and this limits the production. Mergers and acquisitions and other forms of strategic alliances can…
Bacterial Conjunctivitis Drugs Market Driven by Rising Incidence of Ophthalmic B …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as…
